Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial-Reference-Cited by-同舟云学术

Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial

Published:2017-04-13 Issue:8 Volume:115 Page:917-923
ISSN:0022-4790
Container-title:Journal of Surgical Oncology
language:en
Short-container-title:J Surg Oncol

Author:

Bear Harry D.¹^ORCID,Wan Wen¹,Robidoux André²,Rubin Peter³,Limentani Steven⁴,White Richard L.⁴^ORCID,Granfortuna James³,Hopkins Judith O.⁵,Oldham Dwight⁶,Rodriguez Angel⁷,Sing Amy P.⁸

Affiliation:

1. Virginia Commonwealth University and Massey Cancer Center; Richmond Virginia

2. Centre Hospitalier de l'Universite de Montreal; Montreal, Quebec Canada

3. Cone Health Cancer Center; Greensboro North Carolina

4. Carolinas Medical Center; Charlotte North Carolina

5. Forsyth Regional Cancer Center; Winston Salem North Carolina

6. Lynchburg Hematology Oncology Clinic; Lynchburg Virginia

7. Methodist Hospital; Houston Texas

8. Genomic Health, Inc.; Redwood City California

Funder

National Cancer Institute

Genomic Health

Publisher

Wiley

Subject

Oncology,General Medicine,Surgery

Reference46 articles.

1. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18;Fisher;J Clin Oncol,1997

2. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer;Fisher;J Clin Oncol,1998

3. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European cooperative trial in operable breast cancer;Gianni;J Clin Oncol,2009

4. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-27;Bear;J Clin Oncol,2003

5. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute;Bonadonna;J Clin Oncol,1998

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer;Cancer Treatment Reviews;2024-02

2. Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP;Journal of Clinical Oncology;2023-09-20

3. PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to neoadjuvant chemotherapy in ER+/HER2- breast cancer;Frontiers in Oncology;2023-08-28

4. The Added Prognostic Value of Oncotype Recurrence Score to AJCC Prognostic Staging System in Stage III ER+/HER2− Breast Cancer;Advances in Therapy;2023-06-29

5. Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer;Breast Cancer Research and Treatment;2023-03-10